Skip to content
  • Clinical Evidence
  • PAD
    • PAD
    • DETOUR System
    • DETOUR System Evidence
    • DETOUR System Resources
    • DETOUR System Reimbursement
  • AAA
    • AAA
    • ALTO
    • AFX2
    • EVAR for Women
    • EVAR Portfolio Resources
  • Procedural Training
  • For Patients
  • About Us
    • About Us
    • News
    • The Team
    • Careers
    • Contact Us
  • Clinical Evidence
  • PAD
    • PAD
    • DETOUR System
    • DETOUR System Evidence
    • DETOUR System Resources
    • DETOUR System Reimbursement
  • AAA
    • AAA
    • ALTO
    • AFX2
    • EVAR for Women
    • EVAR Portfolio Resources
  • Procedural Training
  • For Patients
  • About Us
    • About Us
    • News
    • The Team
    • Careers
    • Contact Us
Back to News
  • May 2, 2018

Endologix Appoints John Onopchenko as Chief Executive Officer

PrevPreviousEndovascular Aneurysm Sealing (EVAS) with Nellix System Associated with Higher Survival than Traditional Endovascular Aneurysm Repair (EVAR) in New Study
NextEndologix Appoints Jeffry Fecho as Chief Quality OfficerNext
FIND IFU HERE
Youtube Linkedin Twitter

Compliance

Privacy Policy

Safety Information

Anti-Trafficking/Modern Slavery

Cookie Policy

Terms & Conditions

Patents

© 2025 Endologix LLC. All rights reserved.

Endologix® products and associated components are not available in all countries or regions. Please contact your Endologix representative for details regarding product availability. Prior to use, refer to the “Instructions for Use” for complete and specificindications, contraindications, all warnings and precautions. Rx only.